CLOSE
SEARCH FOR
Book a Meeting

IgA Antibody Application for Vaccine Development

More Info

As a world-leading service provider, Creative Biolabs has accumulated extensive experience from the accomplishment of different antibody development projects. During this process, we have accomplished numerous challenging projects of IgA antibodies based vaccine service and received a lot of recognition and praise from our clients. We are very proud to provide our valued customers with high-quality services to eliminate the difficulties in your project.

Background of IgA-based Vaccine

Immunoglobulin A (IgA) is an antibody that plays an important role in mediating immune protection. The studies have demonstrated that IgA deficiency is strongly associated with a wide variety of diseases. The individual with IgA-deficiency has an increased risk of developing autoimmune diseases, such as coeliac disease. Meanwhile, the high expression of serum IgA can be found in a series of acquired immune deficiency syndrome (AIDS) and inflammatory bowel disease. Secretory IgA (S-IgA) molecule, which is composed of dimeric IgA antibody linked by J chain and secretory component, is the representative of the immune response in mucosal tissue. S-IgA antibody is the main immunoglobulin in exocrine secretion and also plays an antimicrobial role in epithelial cell transport. It is the best-defined entity to provide specific immune protection for mucosal surface by blocking bacterial and viral attachment. The S-IgA-based antibody against bacterial pathogens effectiveness and efficacy accelerate IgA antibodies applied for vaccine development. At present, several mucosal IgA vaccines have shown their promising protection in animal models, suggesting a new possibility of using IgA to develop vaccines against diseases.

Schematic representation of the IgA.Fig.1 Schematic representation of the IgA. (Woof, 2006)

The Application of IgA Antibody for Vaccine Development

Secretory IgA (sIgA) has played a key role in regulating infection caused by virus or bacteria, indicating the potential in vaccine development. Experiments have been carried out to genetically engineer secretory components (SC) to provide a protective foreign epitope associated with IgA, so that S-IgA itself can be used as a mucosal vaccine vector. This "antigenized" S-IgA can be recognized by an invasive specific monoclonal antibody, which can survive in the harsh gastrointestinal environment and induce an immune response when taken orally, including antibodies against invasive B cells and SC vectors. These suggest that antigenized IgA/S-IgA can provide a safe mucosal vaccine delivery system for microorganisms and other peptide antigens. Therefore, mucosal and systemic immunity can be achieved by oral administration of such recombinant S-IgA molecule, carrying a protective bacterial epitope in the primary sequence of SC polypeptide.

Mechanisms of induction of mucosal IgA and their protection role at mucosal surfaces. Fig.2 Mechanisms of induction of mucosal IgA and their protection role at mucosal surfaces. (Boyaka, 2017)

Our Services for Vaccine Development

Creative Biolabs offers a number of IgA antibodies of different species to meet any requirement of vaccine development. Furthermore, we also provide a panel of IgA-based vaccine development services, which includes but are not limited to:

  • Mucosal vaccine development targeting various cells
  • New Vaccine adjuvants selection for induction of S-IgA
  • The improvement of vaccine delivery systems for S-IgA inducing vaccines
  • The immunogenicity and safety evaluation of vaccine

Creative Biolabs is recognized as the world leader for providing the most diverse portfolio of antibody development solutions for worldwide customers. We are always dedicated to assisting our clients with the most satisfactory IgA related services. If you are interested in our services, please do not hesitate to contact us for more details.

References

  1. Woof, J. M., et al. The function of immunoglobulin A in immunity. J Pathol. 2006, 208(2): 270-282.
  2. Boyaka, P. N., et al. Inducing mucosal IgA: A challenge for vaccine adjuvants and delivery systems. J Immunol. 2017, 199(1): 9-16.

KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.

Online Inquiry

For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.

CONTACT US

USA

Tel:

Fax:

Email:

Stay Up To Date
Subscribe

© 2022 Creative Biolabs All Rights Reserved